Eli Lilly and Company (LLY)

US — Healthcare Sector
Peers: JNJ  ABBV  AZN  NVO  NVS  AMGN  MRK  GILD  PFE  SNY 

Automate Your Wheel Strategy on LLY

With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol LLY
  • Rev/Share 59.3141
  • Book/Share 20.4356
  • PB 39.4497
  • Debt/Equity 2.1838
  • CurrentRatio 1.2777
  • ROIC 0.277

 

  • MktCap 722030480052.0
  • FreeCF/Share -0.0559
  • PFCF -14383.0773
  • PE 52.2367
  • Debt/Assets 0.3954
  • DivYield 0.0072
  • ROE 0.8836

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Reiterated LLY BMO Capital Markets -- Outperform $840 $930 Oct. 20, 2025
Upgrade LLY Erste Group Hold Buy -- -- Oct. 14, 2025
Downgrade LLY Berenberg Buy Hold -- $830 Sept. 17, 2025
Upgrade LLY HSBC Securities Reduce Hold -- $700 Aug. 27, 2025
Downgrade LLY Daiwa Securities Outperform Neutral -- $700 Aug. 18, 2025
Downgrade LLY Leerink Partners Outperform Market Perform -- $715 Aug. 7, 2025
Downgrade LLY Erste Group Buy Hold -- -- June 5, 2025
Downgrade LLY HSBC Securities Buy Reduce $1150 $700 April 28, 2025
Initiation LLY Cantor Fitzgerald -- Overweight -- $975 April 22, 2025
Resumed LLY BofA Securities -- Buy -- $997 Dec. 10, 2024

News

Eli Lilly Q3 earnings eyed for insights into drug pricing policies, obesity and diabetes drug performance
LLY
Published: October 20, 2025 by: Proactive Investors
Sentiment: Neutral

Eli Lilly and Co (NYSE:LLY) will report its third quarter 2025 earnings next Thursday, with Bank of America analysts closely watching how the company's obesity and diabetes treatments are performing amid ongoing policy debates over US drug pricing. The firm believes the drugmaker's upcoming report could offer insight into the company's key brands while highlighting broader industry trends affecting margins and growth.

Read More
image for news Eli Lilly Q3 earnings eyed for insights into drug pricing policies, obesity and diabetes drug performance
My Top 3 Pharma Stocks
AKRO, BMY, ETNB, LLY, MRK, NVO, PFE, RHHBY, SPY
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive

Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.

Read More
image for news My Top 3 Pharma Stocks
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
LLY
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
LLY, NVO
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Negative

Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.

Read More
image for news NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks
LLY, NVO
Published: October 17, 2025 by: Investopedia
Sentiment: Negative

Novo Nordisk (NVO) and Eli Lilly (LLY) shares slumped in early trading Friday after President Trump promised to lower the prices of popular weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound.

Read More
image for news Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks
Is Trump Going to Kill the GLP-1 Cash Cow?
HIMS, LLY, NVO
Published: October 17, 2025 by: 24/7 Wall Street
Sentiment: Negative

GLP-1 drugs propelled Novo Nordisk (NVO) and Eli Lilly (LLY) to record profits, with sales exceeding $20 billion amid skyrocketing demand. Both companies cut prices recently to expand access, but President Trump's vow threatens deeper reductions.

Read More
image for news Is Trump Going to Kill the GLP-1 Cash Cow?
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
LLY, PFE
Published: October 17, 2025 by: Benzinga
Sentiment: Negative

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare valuations from Eli Lilly And Co (NYSE:LLY) to Pfizer Inc (NYSE:PFE).

Read More
image for news Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
Novo Nordisk, Eli Lilly shares drop as Trump promises lower weight loss drug prices
LLY, NVO
Published: October 17, 2025 by: Proactive Investors
Sentiment: Negative

Shares of Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY), two major pharmaceutical companies that produce weight-loss drugs, dropped sharply following comments from US president Donald Trump about reductions in the prices of these medicines. During a White House event focused on fertility treatments and drug pricing, Trump suggested that the cost of drugs like Novo Nordisk's Ozempic (semaglutide), used for diabetes and weight management, would soon be “much lower.

Read More
image for news Novo Nordisk, Eli Lilly shares drop as Trump promises lower weight loss drug prices
LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins
LLY
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Eli Lilly's oral GLP-1 pill orforglipron delivers strong A1C reductions in two late-stage diabetes studies, reinforcing its 2026 filing plans.

Read More
image for news LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins
How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?
LLY
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Neutral

Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.

Read More
image for news How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?
Eli Lilly: Outstanding Orforglipron Data Reinforces Value Proposition
LLY
Published: October 15, 2025 by: Seeking Alpha
Sentiment: Positive

Eli Lilly and Company reported strong Phase 3 results for its oral GLP-1 drug orforglipron in type 2 diabetes, meeting all primary and secondary endpoints. LLY's GLP-1 franchise, including Mounjaro, Zepbound, and orforglipron, underpins its $800bn valuation and continued bullish long-term growth outlook. Despite high valuation and industry headwinds, LLY's management, product pipeline, and market dominance support a 20% upside potential over 18-24 months.

Read More
image for news Eli Lilly: Outstanding Orforglipron Data Reinforces Value Proposition
How LLY Stock Delivered $47 Billion To Shareholders
LLY
Published: October 15, 2025 by: Forbes
Sentiment: Positive

In the last decade, Eli Lilly stock (NYSE: LLY) has returned $47 billion to its shareholders via dividends and buybacks. This shareholder-centric approach has delivered solid results in 2025, with the stock posting 9% year-to-date returns, despite experiencing some volatility from its peak of $937 earlier in the year, while demonstrating remarkable resilience in the face of increased competition in the diabetes and obesity treatment markets.

Read More
image for news How LLY Stock Delivered $47 Billion To Shareholders
Eli Lilly: The Rally Has More Room To Run (Rating Upgrade)
LLY
Published: October 13, 2025 by: Seeking Alpha
Sentiment: Positive

Eli Lilly stock has recovered resoundingly, outperforming the S&P 500, Novo Nordisk, and healthcare peers after a period of decline. LLY's robust pipeline, expansion into cardiometabolic and oncology adjacencies, and manufacturing readiness support its competitive edge over NVO. Despite near-term gross margin pressures, LLY's valuation is de-risked, and its growth strategy could bolster near-term catalysts from its diversified pipeline.

Read More
image for news Eli Lilly: The Rally Has More Room To Run (Rating Upgrade)
Roche, Lilly's blood test for Alzheimer's diagnosis gets US approval
LLY, RHHBY
Published: October 13, 2025 by: Reuters
Sentiment: Positive

Roche Diagnostics said on Monday the U.S. Food and Drug Administration cleared its and partner Eli Lilly's blood test as an aid in the initial assessment for Alzheimer's disease.

Read More
image for news Roche, Lilly's blood test for Alzheimer's diagnosis gets US approval
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?
ABBV, LLY
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive

Lilly's explosive GLP-1 growth and AbbVie's post-Humira rebound set up a fierce 2025 showdown between two pharma powerhouses.

Read More
image for news AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?
A Pricing Powerhouse, Now 30% Cheaper: Is Eli Lilly Stock A Buy?
LLY
Published: October 09, 2025 by: Forbes
Sentiment: Positive

Eli Lilly (LLY) stock merits your attention. Why? Because it offers monopoly-like high margins at a reduced price.

Read More
image for news A Pricing Powerhouse, Now 30% Cheaper: Is Eli Lilly Stock A Buy?
Former FDA vaccine chief Peter Marks joins Eli Lilly, STAT reports
LLY
Published: October 07, 2025 by: Reuters
Sentiment: Positive

Peter Marks, the former top vaccine regulator at the U.S. Food and Drug Administration, has joined Eli Lilly , STAT News reported on Tuesday.

Read More
image for news Former FDA vaccine chief Peter Marks joins Eli Lilly, STAT reports
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
LLY
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
GSK, LLY
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Read More
image for news Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know
LLY
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive

LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.

Read More
image for news Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know
Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
JNJ, LLY, PFE
Published: October 06, 2025 by: MarketBeat
Sentiment: Neutral

When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue.

Read More
image for news Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
My Top 5 Biotech Stocks Big Pharma Could Buy Next
ABBV, ALVO, AMGN, ARKG, AZN, BIIB, BMY, CSLLY, GILD, GRFS, GSK, IBB, INCY, JNJ, KMDA, LEGN, LLY, MRK, NVS, PFE, PHAT, RDY, REGN, RHHBY, SDZNY
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.

Read More
image for news My Top 5 Biotech Stocks Big Pharma Could Buy Next
"Exciting Race" Between LLY & NVO, Tariffs Remain Long-Term Overhang
LLY, NVO
Published: October 06, 2025 by: Schwab Network
Sentiment: Neutral

Lee Brown sees lots of potential in the weight loss drug space, noting Eli Lilly (LLY) and Novo Nordisk (NVO) as the two companies he expects to lead. He points to "incredible" discounts and expanded access to GLP-1s as indicators these companies will see wider moats for their products.

Read More
image for news "Exciting Race" Between LLY & NVO, Tariffs Remain Long-Term Overhang
Top 50 High-Quality Dividend Growth Stocks For October 2025
AAPL, ACN, ALLE, AMAT, APH, CTAS, DHI, DKS, DPZ, EOG, FAST, FDS, GGG, GRMN, GWW, HCA, HD, HSY, JKHY, KLAC, LECO, LLY, LRCX, MLI, MPWR
Published: October 03, 2025 by: Seeking Alpha
Sentiment: Positive

I track a universe of 50 high-quality dividend growth stocks to identify opportune investments based on valuation and future return potential. As of October 2, 2025, 22 stocks offer attractive future return estimates of at least 10%, with 15 appearing potentially undervalued by my Free Cash Flow model. Top-ranked stocks include MKTX, RMD, MPWR, RACE, and MSCI, each offering strong projected returns driven by yield, valuation upside, and EPS growth.

Read More
image for news Top 50 High-Quality Dividend Growth Stocks For October 2025
Kernal Bio Joins Lilly Gateway Labs to Accelerate In Vivo Cell Therapies
LLY
Published: October 03, 2025 by: Business Wire
Sentiment: Neutral

BOSTON--(BUSINESS WIRE)-- #AI--Kernal Bio retains strategic independence, while gaining access to shared resources, operational support and Lilly's global network of experts.

Read More
image for news Kernal Bio Joins Lilly Gateway Labs to Accelerate In Vivo Cell Therapies
Buy LLY Stock At $820?
LLY
Published: October 03, 2025 by: Forbes
Sentiment: Positive

The entire pharmaceutical sector is experiencing a rerating this week, as investors realize the adverse impact of tariffs and drug price cuts won't be as severe as previously anticipated. While most major pharma stocks have rallied, Eli Lilly stock (NYSE: LLY) warrants particular attention.

Read More
image for news Buy LLY Stock At $820?
How I Would Build An Ultra-High-Conviction Retirement Portfolio Right Now
AM, CBOE, CGDV, CSWC, DIVO, ELS, EME, FIX, FVR, GE, ICAP, JEPQ, KMI, KRC, LB, LHX, LLY, MO, MPLX, MSFT, NVDA, O, ODFL, OWL, PFXF
Published: October 03, 2025 by: Seeking Alpha
Sentiment: Neutral

Building a resilient retirement portfolio requires a mix of disruption-proof income from REITs, midstream energy, and high-yielding assets, plus growth stocks and ETFs. Current market challenges—AI disruption, weak job market, inflation risks—make long-term planning difficult, but also highlight the need for self-reliance and diversification. Core portfolio holdings should include large, proven REITs, natural gas midstream companies, select high-yield stocks, BDCs, preferred equity ETFs, and actively managed income funds.

Read More
image for news How I Would Build An Ultra-High-Conviction Retirement Portfolio Right Now
Why Eli Lilly Is The Lion's Share Of My Portfolio
LLY
Published: October 02, 2025 by: Seeking Alpha
Sentiment: Positive

Healthcare is underowned; 2026 rate cuts and policy clarity should trigger inflows. As XLV's largest weight and obesity leader, Lilly will capture outsized demand during the sector re-rating cycle. Orforglipron, first true oral GLP-1, solves compliance issues and expands TAM. LLY's $1B pre-launch inventory and $15B+ capex signal FDA approval certainty and industrialized pill-based obesity treatment scale. Diversified growth via Alzheimer's, immunology, and oncology pipelines, backed by disciplined governance and supply-first execution. Supports long-term compounding and >40% 12-month upside from $830, with re-rating potential toward ~35× P/E.

Read More
image for news Why Eli Lilly Is The Lion's Share Of My Portfolio
Another Surging Pharma Stock to Watch Right Now
LLY
Published: October 01, 2025 by: Schaeffers Research
Sentiment: Positive

Pharmaceutical concern Eli Lilly And Co (NYSE:LLY ) is charging 7.2% higher to trade at $821.20 this afternoon.

Read More
image for news Another Surging Pharma Stock to Watch Right Now
Top Stock Movers Now: Nike, Eli Lilly, Corteva, AES, and More
AES, CTVA, LLY, NKE
Published: October 01, 2025 by: Investopedia
Sentiment: Negative

The S&P 500, Dow, and Nasdaq were little changed Wednesday afternoon, as a federal government shutdown took effect.

Read More
image for news Top Stock Movers Now: Nike, Eli Lilly, Corteva, AES, and More

About Eli Lilly and Company (LLY)

  • IPO Date 1972-06-01
  • Website https://www.lilly.com
  • Industry Drug Manufacturers - General
  • CEO David A. Ricks
  • Employees 47000

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.